Onco Actu du 27 avril 2015

	3.1 Tabac
What We Can All Learn As New Orleans Shows The Way To A Healthier, Smoke-Free City [Dr Len] Six months ago, there weren't many who thought this could happen, that the City Council of New Orleans would pass and the Mayor would sign a smoke-free bar and casino ordinance in New Orleans. But pass it they did, and now it's the law.
India vows to press tobacco companies for bigger health warnings [Reuters] "The warnings currently are very weak," said Seema Gupta, an official of nonprofit health and development network the Voluntary Health Association of India. "The delay will lead to an increase in the number of tobacco users."
Hawaii lawmakers pass bill raising smoking age to 21 [Reuters] The bill, which passed the state Senate by a vote of 19-4 after clearing the house last week, would also ban the sale, purchase or use of electronic cigarettes for those under the age of 21.
	4.9 Dép., diag. & prono. - Sein
U.S. data show that mammograms still often begin at 40 [Reuters] Screening rates were lower overall in 2010 and 2012 than in previous years, the authors report in the American Journal of Preventive Medicine, but the proportion of women who began getting screened at age 40 increased, and was highest after the USPSTF recommendations were issued in 2009.
	5. Traitements
Radiotherapy or Not in Older Women Receiving Breast-Conserving Surgery and Endocrine Treatment? [The ASCO Post] Study shows omitting radiotherapy may increase local recurrence risk but has no effect on survival.
Trial of radioactive implants offers improved prostate cancer survival [The Guardian] “Although, to date, overall survival and prostate cancer-specific survival do not appear to differ between the two groups, existing trends favour LDR-PB and an overall survival advantage is likely to emerge with longer follow-up.”
	5.12 Immunothérapies
Natural Defenses [Genome Mag] “This is not the end of the road for this technology at all,” says Brentjens. “We have a Model A Ford, and we want to build a Ferrari.”
	5.2 Pharma
Sanofi dumps an ImmunoGen cancer drug as it scales back in oncology [FierceBiotech] ImmunoGen disclosed that Sanofi has abandoned SAR3419, an antibody-drug conjugate designed to treat diffuse large B-cell lymphoma (DLBCL) and other blood cancers.
	5.2.1 Pharma - Partenariats
AstraZeneca lends its oncology star to Celgene and recruits Innate in a PD-L1 deal spree [FierceBiotech] The pair of pacts comes just a day after AstraZeneca partnered up with Juno Therapeutics to test that company's pioneering CAR-T technology with MEDI4736 in blood cancers.
AstraZeneca Inks $1.8B in Immuno-Oncology Deals as Q1 Profit Dips [GEN] AstraZeneca CEO Pascal Soriot defended the recent deals on a conference call: “It's more strategically driven than financially driven, though of course the financial aspects also help.”
AstraZeneca and Innate Pharma announce global co-development and commercialisation collaboration for IPH2201 in immuno-oncology [AstraZeneca] The initial development plan includes: Phase II combination clinical trials with MEDI4736 in solid tumours; multiple Phase II trials planned by Innate to study IPH2201 both as monotherapy and in combination with currently approved treatments across a range of cancers; and the development of associated biomarkers.
Celgene Corporation Enters into Strategic Immuno-Oncology Collaboration with AstraZeneca to Develop PD-L1 Inhibitor Program for Patients with Serious Blood Cancers [Celgene] MEDI4736 is a human monoclonal antibody directed against programmed cell death ligand 1 (PD-L1), which helps tumors avoid detection by the immune system. Tumor cells use PD-L1 to turn off the immune system just as it begins to mount a response against them. MEDI4736 helps turn the immune system back on, allowing it to continue its attack on cancer.
AstraZeneca announces new cancer deals with first-quarter results [The Guardian] The Anglo-Swedish drugmaker also announced an alliance with US blood cancer specialist Celgene to develop and sell AstraZeneca’s MEDI4736 – one of its most promising new cancer drugs – across a range of blood cancers including non-Hodgkin’s lymphoma. Another licensing deal with Innate Pharma will combine the same drug with an antibody developed by the French biotech firm.
Astrazeneca drug deal hoists Innate Pharma shares to record high [Reuters] It is the most significant transaction ever by the Marseille-based biopharmaceutical company, worth about 700 million euros on the stock market even after Friday's share price jump.
	5.3 Traitements - FDA, EMA,...
Bristol-Myers Squibb Receives Positive CHMP Opinion in the European Union for Opdivo (nivolumab) for the Treatment of Advanced Melanoma in Both First-Line and Previously Treated Patients [BMS] Application supports the use of Opdivo in both BRAF wild-type and mutation positive melanoma patients.
Lilly's CYRAMZA® (ramucirumab) Receives Fourth FDA Approval [Lilly] CYRAMZA Now Approved in the U.S. for Use with FOLFIRI in Second-Line Treatment of Metastatic Colorectal Cancer.
New treatment for advanced melanoma [EMA] Opdivo offers treatment option for patients with poor prognosis.
EMA Recommends Granting a Marketing Authorisation for Nivolumab [ESMO] Detailed recommendations for the use of this product will be described in the summary of product characteristics, which will be published in the European public assessment report and made available in all official European Union languages after the marketing authorisation has been granted by the European Commission.
	5.4 Traitements - Economie
In Search of ‘Just’ Prices: Questioning the High Cost of New Cancer Drugs [The ASCO Post] As physicians guided by the Hippocratic oath, it is up to us to stand up for our patients and counter the people and institutions that have a vested interest in keeping cancer drugs priced at an artificially inflated rate. As doctors, we should be strong advocates for our patients.
	5.6 ESMO
Abstract Submission | Immuno-Oncology 2015 | Cancer Immunotherapy [ESMO] Share your research! Submit your abstract for the ESMO Symposium on Immuno-Oncology 2015 - Lausanne, Switzerland 20-21 November 2015.
	5.9.6 AACR - prostate
Breast cancer drug may help men with prostate cancer [Science] Although genetic tests of tumors are already used to determine whether certain drugs will work for several types of cancer, this is the first time researchers have found such a test for prostate cancer, de Bono’s group says. Olaparib could offer a new option for these men.
	6. Lutte contre les cancers
The Future of Cancer: Closer to a Cure [Wall Street Journal] Sloan Kettering CEO Craig Thompson on the revolution under way in cancer prevention and treatment.
'Embryologic twin' tumour discovered in student's brain [BBC News] The growth, known as a teratoma, had bone and hair. Ms Karanam, a student at Indiana University, jokingly described the tumour to KNBC, a California TV station, as her "evil twin sister who's been torturing me for the past 26 years".
	6.10 Politiques
Election 2015: what are the parties from Scotland, Wales and Northern Ireland saying about cancer? [Cancer Research UK] With the outcome of the election proving difficult to predict, the potential role of these smaller parties has never been bigger. So we’ve been analysing the manifestos from the parties in each of the devolved nations to find out what’s relevant for cancer, the NHS, and research more broadly.
	6.11 Patients
As a clinical oncologist I'm amazed at how patients and their families cope [The Guardian] Despite patients’ difficult situations with brain tumours, people who visit the clinic are surprised by how much laughter there is.
	6.6 Publications
Bar graphs criticized for misrepresenting data [Nature News & Comment] Dodgy data analysis has come under fire in recent months, and now an article in PLoS Biology1takes aim at another staple of statistics. It argues that bar graphs used to describe a continuum of data are often uninformative and misleading, and should be purged from much of the scientific literature.
	6.7 DMP, Big Data & applis
Health apps: a note of caution [Cancer Research UK] Health apps (applications that offer health-related services on your mobile phone or tablet) areflooding the market. And the same goes for wearable technology, or ‘wearables’, like the Fitbit, JawBone and most recently the Apple Watch. But how much can we rely on this technology? And does it actually do us any good?